Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 28, 2021
Reporting Period: Event date June 28, 2021; Closing expected on or about July 2, 2021.
Context: The Company entered into a Securities Purchase Agreement for a private placement offering of approximately $12 million in securities to an institutional accredited investor.
Key Financial Metrics
Offering Details:
- Gross Proceeds: Approximately $12 million.
- Net Proceeds: Estimated at approximately $11 million.
- Securities Issued:
- 890,000 Common Shares.
- 3,146,327 Pre-Funded Warrants (exercisable at $0.0001).
- 4,036,327 Series A Warrants (exercise price $2.848, 5-year term).
- Purchase Price: $2.973 per Share/Warrant; $2.9729 per Pre-Funded Warrant.
Placement Agent Fees:
- Cash fee: 7.5% of gross proceeds.
- Warrant fee: Warrants to purchase 7.5% of the aggregate number of Shares and Pre-Funded Warrants placed.
Use of Proceeds: Pipeline development, business development activities, and general working capital.
Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
This filing reports a material definitive agreement (Item 1.01) rather than a periodic financial update. The primary material change is the execution of the private placement agreement, which will increase the Company's cash position by approximately $11 million upon closing and increase the number of outstanding shares and warrants significantly.
Guidance, Outlook, and Risks
Management Commentary: Proceeds are designated to advance the Company's pipeline and business development.
Outlook: Closing is expected on or about July 2, 2021, subject to customary conditions.
Risks and Contingencies:
- Beneficial Ownership Limitation: The Investor cannot exercise warrants if it would cause beneficial ownership to exceed 4.99% of outstanding shares.
- Registration Rights: The Company must file a registration statement for the resale of shares within ten business days of the agreement date.
- Regulatory Exemptions: Securities are sold under Section 4(a)(2) and Regulation D exemptions; resale is restricted until a registration statement is effective or an exemption applies.
Investor Verification Checklist
- Confirm the actual closing date and final net proceeds received (expected ~July 2, 2021).
- Verify the filing of the registration statement for the resale of shares within the required ten-business-day window.
- Monitor the impact of the new share issuance and warrant exercises on existing shareholder dilution.
- Review the specific terms of the Placement Agency Agreement regarding expense reimbursements and tail rights.